Search Results - "Sokareva, Ekaterina"

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis by Rossing, Peter, Bain, Stephen C., Bosch-Traberg, Heidrun, Sokareva, Ekaterina, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G.

“…BackgroundSemaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have…”
Get full text

Lifestyle modification program, LIFE is LIGHT, in patients with type 2 diabetes mellitus and obesity: Results from a 48‐week, multicenter, non‐randomized, parallel‐group, open‐label study by Galstyan, Gagik R., Valeeva, Farida V., Motkova, Svetlana I., Surkova, Elena V., Savelyeva, Larisa V., Rudina, Larisa M., Ramanathan, Krishnan, Sokareva, Ekaterina, Bondareva, Kristina, Shestakova, Marina V.

“…Background Obesity is a potential risk factor for development of type 2 diabetes mellitus (T2DM). To achieve long‐term weight reduction in patients with T2DM…”
Get full text

4441 KIDNEY DISEASE OUTCOMES WITH SEMAGLUTIDE VERSUS PLACEBO ACROSS BASELINE KDIGO RISK CATEGORIES: A POST HOC ANALYSIS OF SUSTAIN 6 by Tuttle, Katherine, Bain, Stephen C, Bosch-Traberg, Heidrun, Cherney, David, Rasmussen, Søren, Sokareva, Ekaterina, Khunti, Kamlesh

Get full text

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial by Mahaffey, Kenneth W, Tuttle, Katherine R, Arici, Mustafa, Baeres, Florian M M, Bakris, George, Charytan, David M, Cherney, David Z I, Chernin, Gil, Correa-Rotter, Ricardo, Gumprecht, Janusz, Idorn, Thomas, Pugliese, Giuseppe, Rasmussen, Ida Kirstine Bull, Rasmussen, Søren, Rossing, Peter, Sokareva, Ekaterina, Mann, Johannes F E, Perkovic, Vlado, Pratley, Richard

“…In the FLOW trial, semaglutide reduced the risks of kidney and cardiovascular (CV) outcomes and death in participants with type 2 diabetes mellitus (T2D) and…”
Get full text

Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial by Tuttle, Katherine R., Bain, Stephen C., Bosch-Traberg, Heidrun, Khunti, Kamlesh, Rasmussen, Søren, Sokareva, Ekaterina, Cherney, David Z.

“…Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are recommended by Kidney Disease: Improving Global Outcomes (KDIGO) as risk-based treatment for…”
Get full text